Skip to content

Nilotinib attenuates NLRP3 inflammasome activation and GSDMD/NINJ1-mediated pyroptosis via modulation of NF-κB signaling and enhancement of BAG3-dependent aggrephagy and ESCRT-III-mediated plasma membrane repair in microglia.

Aug 2026 · Journal of Neuroimmunology · Vol 421, pp. 579084 · 0 citations · 43 references
Medicine

TL;DR

The results reveal that nilotinib exerts a multi-layered regulatory effect on microglial inflammatory responses by suppressing inflammasome activation and pyroptosis while promoting autophagy-dependent clearance and membrane repair pathways.

Abstract

Microglia are the resident immune cells of the brain and serve as key regulators of innate immune responses within the central nervous system (CNS). The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is a multiprotein complex that plays a central role in innate immunity, and its excessive activation contributes to the pathogenesis of neurodegenerative diseases. Nilotinib, a second-generation tyrosine kinase inhibitor, has recently attracted attention due to its neuroprotective and immunomodulatory properties in the CNS. In the present study, we investigated the effects of nilotinib on NLRP3 inflammasome activation, GSDMD/NINJ1-mediated pyroptosis, NF-κB signaling, BAG3-dependent aggrephagy, and ESCRT-III-mediated plasma membrane repair in LPS plus ATP-induced murine N9 microglial cells. Our findings demonstrated that nilotinib significantly attenuated NLRP3 inflammasome activation, as evidenced by reduced NLRP3 expression, decreased caspase-1 activation, and suppressed secretion of proinflammatory cytokines IL-1β and IL-18 through modulation of the IκBα/NF-κB signaling axis. Furthermore, nilotinib markedly inhibited pyroptotic cell death by reducing GSDMD-N and NINJ1 expression, thereby preserving membrane integrity. In parallel, nilotinib enhanced BAG3-dependent selective autophagy and increased LC3B expression, suggesting activation of aggrephagy pathways involved in the clearance of inflammasome-associated components. Notably, nilotinib also restored VPS4A expression, indicating activation of ESCRT-III-mediated plasma membrane repair mechanisms. Collectively, our results reveal that nilotinib exerts a multi-layered regulatory effect on microglial inflammatory responses by suppressing inflammasome activation and pyroptosis while promoting autophagy-dependent clearance and membrane repair pathways. These findings highlight a novel integrative mechanism linking autophagy, pyroptosis, and membrane repair in the neuroprotective actions of nilotinib.

View source

Similar papers

Sep 2026

NNV mediates the activation of the NLRP3 inflammasome through mtDNA release and oxidative DNA damage.

The NLRP3 inflammasome is a cytoplasmic multiprotein complex that is activated under stress or infection conditions. It promotes the maturation of IL-1β by cleaving pro-Caspase-1, thereby playing a critical role in host innate immune responses. Various viruses can differentially activate NLRP3 through distinct mechanis...

Li-Fang Cao, Run-Bin Huang, Lu Yang et al. · 0 citations
Open access Sep 2026

Deoxynivalenol triggers pyroptosis in intestinal epithelial cells via NLRP3 inflammasome activation mediated by the TLR4-NF-κB/p38 MAPK signaling pathway.

TLR4 inhibition with TLR4-IN-C34 confirmed that TLR4 acts as an upstream regulator controlling both NF-κB and p38 MAPK signaling, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis.

Wang-Yong Yu, Ya-Fei Sun, Ming-Yue Wang et al. · 0 citations
Open access Sep 2026

MCC950-Derived NLRP3 Inflammasome Inhibitor Modulates Glial Inflammatory Signatures and Neuroinflammation after Traumatic Brain Injury

It is demonstrated that compound 4b exerts NLRP3 inhibitory activity in CNS-resident innate immune cells and modulates neuroinflammation and functional recovery after TBI, supporting its further development as a mechanistically validated NLRP3 inhibitor with translational relevance.

Céline Decouty-Pérez, María Álvarez-Rubal, Icíar Polo-Fernández et al. · 0 citations
Aug 2026

Vilazodone inhibits NLRP3 inflammasome assembly by targeting the NACHT domain and alleviates inflammatory disease.

Vilazodone exerted anti-inflammatory effects in vivo, reducing cytokine production in mouse models of MSU-induced peritonitis and LPS-induced systemic inflammation and highlight its potential for repurposing in inflammasome-driven diseases.

Xiang-Yu Yang, Gui-Fang Xiong, Jie Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.